MediWound

Next-Generation Enzymatic Therapeutics For Non-Surgical Tissue Repair

NexoBrid®

Disruptive Therapy for Burn Care FDA and EMA approved

- Approved in 40+ countries; 16,000+ patients treated to date
- Poised to replace standard of care for eschar removal in severe burns
- Minimizes need for surgery and significantly reduces blood loss
- Topical application at bedside
- Preserves viable tissue and improves patient outcomes (scar quality and function)
- c-GMP sterile manufacturing facility to support global demand

EscharEx®

Bioactive Enzymatic Debridement Drug Candidate for Chronic Wounds

- Rapid, effective debridement and facilitation of wound closure for Venous Leg Ulcers (VLU) and Diabetic Foot Ulcers (DFU)
- Easy to use topical application for all patient settings
- Debrides chronic ulcers within 4-8 applications
- Promotes granulation tissue and reduces bacteria & biofilm
- Demonstrated superiority over SANTYL®
- Targets a $2.5B+ market
- De-risked program; based on 3 successful Phase II trials
  - Ongoing Phase III trial for VLU
  - DFU trial planned H2 2026
  - Pressure Ulcers (PU) planned mid-2026
- Research collaborations with Mölnlycke, Solventum, Coloplast, Convatec, MIMEDX and Essity

Global Collaborations

European Commission · BARDA · Department of Defense · MIMEDX · convatec · Mölnlycke · IPM · solventum · KAKEN · VERICEL · Coloplast · essity

Validated Enzymatic Technology Platform

Solid Balance Sheet

$54M cash (as of Dec. 31 2025)

$17M revenues in 2025

$120M BARDA funding (to date)

$18M DoD funding (to date)